Chuck Wentworth

Discontinuation of Lipid Modifying Drugs Among Commercially Insured United States Patients in Recent Clinical Practice

Sachin Kamal‐Bahl, Thomas Burke, Douglas J. Watson et al. · The American Journal of Cardiology · 2006 · 114 citations · Full text

Pharmacy, Clinical Pharmacy, Pharmacotherapy +10

An Evaluation of the THIN Database in the OMOP Common Data Model for Active Drug Safety Surveillance

Xiaofeng Zhou, Sundaresan Murugesan, Harshvinder Bhullar et al. · Drug Safety · 2013 · 84 citations

Pharmacy, Bioinformatics, Biomedical Informatics +16

Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX‐2 specific inhibitors and non‐specific NSAIDs

Sean Z. Zhao, Chuck Wentworth, Thomas Burke et al. · Pharmacoepidemiology and Drug Safety · 2003 · 31 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice

Hemant Phatak, Chuck Wentworth, Vitaliy Sazonov et al. · Atherosclerosis · 2008 · 23 citations

Life Sciences, Pharmacotherapy, Clinical Epidemiology +9

Loss of early gains in low-density lipoprotein cholesterol goal attainment among high-risk patients

JoAnne M. Foody, Shiva G. Sajjan, Xiaohan Hu et al. · Journal of clinical lipidology · 2010 · 22 citations

Medicine, Chronic Disease Prevention, Health Promotion +13